Subjects will be randomized in a 1:1:1:1 ratio to the following dose groups:~X-82 50 mg plus ivt anti-VEGF prn~X-82 100 mg plus ivt anti-VEGF prn~X-82 200 mg plus ivt anti-VEGF prn~Placebo plus ivt anti-VEGF prn~Subjects will be treated for a total of 52 weeks with one of three doses of X-82 or placebo.~Primary Efficacy Outcome:~The primary efficacy outcome is the change in visual acuity score from Day -1 to 52 Weeks after randomization.~Safety Outcomes:~Systemic and ocular safety will be evaluate by assessing ECG, laboratory analyses, adverse events and serious adverse events.~Approximately 132 subjects will be randomized into one of the four arms (33 subjects per dose group).
The purpose of this study is to evaluate the safety and efficacy of X-82 in the treatment of vision loss due to wet AMD.